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Abstract: Parkinson’s disease (PD) is characterized by the loss of dopaminergic neurons in the
substantia nigra and subsequent motor symptoms, but various non-motor symptoms (NMS)
often precede motor symptoms. Recently, NMS have attracted much attention as a clue for
identifying patients in a prodromal stage of PD, which is an excellent point at which to administer
disease-modifying therapies (DMTs). These prodromal symptoms include olfactory loss, constipation,
and sleep disorders, especially rapid eye movement sleep behavior disorder (RBD), all of which are
also important for elucidating the mechanisms of the initiation and progression of the disease. For the
development of DMTs, an animal model that reproduces the prodromal stage of PD is also needed.
There have been various mammalian models reported, including toxin-based, genetic, and alpha
synuclein propagation models. In this article, we review the animal models that exhibit NMS as
prodromal symptoms and also discuss an appropriate prodromal model and its importance for the
development of DMT of PD.
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1. Introduction
Parkinson’s disease (PD) is one of the most common neurodegenerative disorders. It is
characterized by motor symptoms such as bradykinesia, rigidity, tremor, and postural instability, but it
is also well known that a lot of non-motor symptoms often precede motor symptoms. The current
diagnostic criteria for PD are based on motor symptoms [1], but the number of dopaminergic (DA)
neurons in the substantia nigra pars compacta (SNc) has already been reduced by about half [2] when
patients are diagnosed with PD. At present, only symptomatic therapies are available for PD, so both
the establishment of early diagnostic methods and development of disease-modifying therapies (DMTs)
that prevent the onset or slow progression of the disease are urgently needed.
Animal models are essential in a preclinical study for drug development. A lot of models have been
created mainly to reproduce DA cell loss and motor symptoms after the onset. However, models for
the prodromal stage when the DA cell loss is minimal are also necessary for the development of DMTs
in PD, and several models have recently been developed for this purpose [3].
Among the many prodromal symptoms, hyposmia, constipation, and rapid eye movement (REM)
sleep behavior disorder (RBD) are particularly important. The positive likelihood ratios for the future
development of PD in individuals with hyposmia, constipation, and polysomnography-confirmed
RBD are 6.4, 2.5, and 130, respectively [4]. Furthermore, these prodromal symptoms often appear in
combination before the appearance of motor symptoms and attract attention as a clue for determining
the initiation process of the PD pathology. The Braak hypothesis states that pathological alpha synuclein
(α-syn) propagates from the olfactory bulb and/or the lower brainstem, especially from the dorsal
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nucleus of the vagus nerve (DMV) [5]. The olfactory bulb and DMV have contact with the outside of the
body through the olfactory nerve and gastrointestinal (GI) tract, respectively, suggesting the influence
of peripheral factors on the initiation of PD. As for RBD, the nuclei in the ventromedial medulla and
locus subcoerules located in the lower brainstem are thought to be the responsible regions [6] (Figure 1).
Although the olfactory bulb and these lower-brainstem nuclei are spatially separated, hyposmia and
constipation/RBD reportedly appear in a chronologically close period [7], suggesting the multifocal
initiation of PD rather than the simultaneous propagation from the periphery.
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indicate Lewy pathology. Bold red arrows and question marks indicates hypothesized propagation 
pathway of Lewy pathology in human. (B) In a propagation model, α-syn aggregates start from the 
olfactory bulb or the GI tract/ dorsal nucleus of the vagus nerve (DMV), and hyposmia and GI 
dysfunction appear as its corresponding symptoms in a prodromal stage. In contrast, in a α-syn BAC 
transgenic model that mildly overexpresses α-syn in its native expression manner, both of hyposmia 
and RBD are observed with multifocal accumulation of phosphorylated α-syn. Orange dots indicate 
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propagateon pathway in animal experiments. 
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Figure 1. Human Parkinson’s disease (PD) and mouse model in a prodromal stage. (A) In human
PD, Lewy pathology is already present in a prodromal stage in extra central nervous system (CNS)
tissues including GI tract and autonomic nerves, and in the lower brainstem and/or olfactory bulb. As a
prodromal symptom hyposmia, constipation, and rapid eye movement sleep behavior disorder (RBD)
appear in a chronologically close period, suggestive of the multifocal initiation of PD. Black dots indicate
Lewy pathology. Bold red arrows and question marks indicates hypothesized propagation pathway
of Lewy pathology in human. (B) In a propagation model, α-syn aggregates start from the olfactory
bulb or the GI tract/ dorsal nucleus of the vagus nerve (DMV), and hyposmia and GI dysfunction
appear as its corresponding symptoms in a prodromal stage. In contrast, in a α-syn BAC transgenic
model that mildly overexpresses α-syn in its native expression manner, both of hyposmia and RBD are
observed with multifocal accumulation of phosphorylated α-syn. Orange dots indicate accumulateon
of phosphorylated α-syn and bold blue arrows indicate entry zone of injected α-syn. Thin solid arrows
shows main propagateon pathway of α-syn and dotted arrows indicate minor propagateon pathway in
animal experiments.
At present, mammalian models for prodromal PD can be roughly classified into three categories:
toxin-based, genetic, and α-syn propagation models. In this paper, we will focus on olfactory
disturbance (hyposmia), constipation, and RBD as important symptoms in the prodromal stage of PD
and introduce representative animal models for prodromal symptoms. These models are expected not
only to help elucidate the pathomechanisms underlying the initiation and progression of PD but to
play important roles as preclinical models for DMT in PD.
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1.1. Toxin-Based Models
PD is a multifactorial disease caused by the sum of the effects of multiple genetic and environmental
factors. Environmental factors include intestinal flora, inflammation, viruses, and toxicants.
For example, rotenone, a kind of pesticide, causes DA cell death through mitochondrial toxicity [8,9].
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 6-hydroxydopamine (6-OHDA) also act
as neurotoxins against DA neurons [10,11]. Toxin-based animal models have greatly contributed to
the development of symptomatic treatments, mainly for motor symptoms. Furthermore, these toxins
can reproduce the motor complication of anti-Parkinsonian drugs, such as l-dopa-induced dyskinesia,
and is also used to check the efficacy of therapies against motor complications in the advanced
stage of PD [12]. These models have advantages in that the phenotype is clear, the time required
for the experiment is short, and they can be applied to various animal species (Table 1). However,
toxin exposure to the experimenter must be avoided, and criticisms that these kinds or concentrations of
toxins do not exist in the natural environment have been levied. In addition, robust motor phenotypes
can interfere with the analysis of non-motor phenotypes. Nonetheless, some toxin-based models also
show prodromal symptoms and will continue to be useful models in the future.
Table 1. Advantages and disadvantages of each model.
Toxin-Based Model α-syn Transgenic Model α-syn Propagation Model
Phenotype (Motor) Robust Rare Possible (requires reproducibility)
Phenotype (Non-Motor) Rare Widespread Possible (requires reproducibility)
Time Required for
Experiments Short (days~weeks) Long (months~years) Moderate (1~12 months)
Animal Species Applicable tonon-human primates






Risk of exposure to
toxins Off-target effect of transgene
Risk of exposure to fibrils





etiology in human Close to etiology in human
Reproduces a part of etiology in
human
1.2. Genetic and α-syn Propagation Models
One of the most important genetic factors in PD is α-synuclein (SNCA), which is the causative
gene of familial PD. SNCA encodes α-syn, the main constituent of Lewy bodies (LBs), which are
the important pathological feature of PD [13]. Point mutations, such as A53T and A30P, as well
as duplication and triplication of SNCA, also cause PD [14–16]. This means that quantitative and
qualitative changes in α-syn can trigger PD. Furthermore, a genome-wide association study (GWAS)
in PD showed that the highest risk SNP was localized in SNCA [17,18].
With this background, a number ofα-syn transgenic animal models have been created, contributing
to the elucidation of the pathology and treatment for PD [19–27]. The α-syn transgenic model can
reproduce α-syn aggregation similar to human PD and show slowly progressive changes (Table 1).
However, the phenotypes essentially depend on the potent exogenous promoters used to overexpress
α-syn and do not necessarily reflect the spatial and temporal distribution of human PD pathologies.
In addition, it usually takes time and is sometimes difficult to obtain the desirable phenotypes compared
with other methods.
Other genetic models are also created by overexpression or deletion of genes for familial PD.
Genes for familial PD with Lewy bodies and age-dependent progression with non-motor phenotypes
are especially important to reproduce the natural course of idiopathic PD.
Recently, the propagation hypothesis that α-syn can be transmitted by its prion-like property
to form a pathological condition of PD has attracted attention. In clinical trials of fetal DA cell
transplantation in PD, aggregation of α-syn was observed in grafts more than 10 years after
transplantation [28,29]. In mouse experiments, injected α-syn fibrils have been shown to spread
throughout the brain [30]. The propagation model created by exogenously administered α-syn fibrils
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is still in development, but it is relatively easy to obtain a phenotype, and the time required for the
experiment is shorter than with the transgenic model (Table 1). It is also a great advantage that
this model can be applied to non-human primates and other animals as well. However, even if
the propagation hypothesis is true, questions remain concerning where and how the initial α-syn
aggregates are formed, and it should be noted that this model is artificial in nature. In addition,
the method of preparing and injecting fibrils differs among facilities, which impacts the degree of
α-syn propagation and cell loss in this model [31–33].
2. Prodromal Symptoms and Relevant Animal Models
2.1. Prodromal Symptoms of PD Patients
Prodromal symptoms are important as clinical biomarkers to identify patients in a premotor
stage, especially when the fluid and imaging biomarkers are lacking. They include hyposmia,
sleep abnormalities, autonomic dysfunction, and psychiatric problems, and some of the prodromal
symptoms such as anxiety/depression, cognitive decline, and somnolence are much more frequent
and become problematic in an advanced stage. These non-motor symptoms should be weighted
as prodromal biomarkers in terms of the prevalence in PD patients, diagnostic strength to predict
future development of PD, lead time to the diagnosis of PD, and feasibility of assessment and
screening [34]. The highest predictive value for the future development of PD is observed in
polysomnography-confirmed RBD with a positive likelihood of 130, but their prevalence in the general
population is very low (high specificity and low sensitivity) and is not suitable for screening. In contrast,
the predictive value of constipation is moderate with a positive likelihood of 2.5, but the prevalence in
the general population is very high (high sensitivity and low specificity). Hyposmia has moderately
high predictive value with a positive likelihood of 6.4, and its prevalence in the general population is
moderate [4].
The pattern and sequence of these prodromal symptoms may provide important information on
the initiation and mode of progression of PD, and Braak’s staging would help our understandings [5,35].
In Braak staging, lesions in Stage 1–2 is thought to be responsible for prodromal symptoms. Stage
1 includes the DMV that innervates the GI tract and the olfactory bulb, which may correspond to
constipation and olfactory dysfunction, respectively. Constipation is one of the main and most frequent
autonomic dysfunctions of PD, and a case–control study showed that constipation can occur more than
20 years before the onset of motor symptoms [36]. In the pathological analysis, α-syn was found to be
accumulated in the DMV and enteric nervous system [5,37]. In the GI tract, α-syn pathology is stronger
in the rostral part than that in the caudal part [38,39]. Olfactory disturbance has been shown to be
associated with not only PD but also many neurodegenerative diseases. It is observed in more than
90% of sporadic PD patients and appears at least several years before the onset of motor symptoms [40].
In accordance with this clinical observation, α-syn aggregates are observed in the olfactory tract,
even in early-stage PD patients [5]. The number of tyrosine hydroxylase (TH)-positive cells in the
olfactory bulb is markedly increased, and it has been speculated that the inhibition of olfactory
transmission by DA may be responsible for the olfactory disturbance in PD [41]. Stage 2 includes the
raphe nuclei, gigantocellular reticular nucleus of the medulla oblongata, and the locus coeruleus in
the pontine tegmentum [5,35]. These regions can be related to sleep disorders, depression, or anxiety.
Depression and anxiety are observed in 30–45% and 25–49% of PD patients, respectively, in all PD
stages including the prodromal stage [42]. Sleep disorders are one of the most frequent symptoms
in PD and include daytime sleepiness, insomnia, RBD, and restless leg syndrome [43]. Autopsy
brains of idiopathic RBD patients have been reported to show Lewy pathology in the brainstem and
neurodegeneration in the SNc [44,45]. In autopsy brains of PD patients who developed PD and dementia
with Lewy bodies (DLB) preceded by idiopathic RBD, LBs were identified in the pedunculopontine
tegmental nucleus (PPN), locus coeruleus/subcoeruleus complex, and gigantocellular reticular nucleus
in medulla oblongata [46]. These regions are considered part of the neural circuit controlling atonia
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during REM sleep in animal experiments [6,47,48] and thus responsible for RBD. In this way the
pathological progression of PD largely follows Braak’s staging. However, it should be also noted that
the Braak stage does not always correlate with the severity of neuronal loss and associated clinical
symptoms [49].
In this section we will focus on the hyposmia, constipation, and RBD, considering their importance
as prodromal symptoms of PD from the viewpoints of the prevalence in PD patients, diagnostic strength
to predict future development of PD, and feasibility of assessment in animals.
2.2. Prodromal Symptoms of Toxin-Based Models
In the toxin-based model, neuronal death of SNc appears several days or several weeks after toxin
administration [8–12]. Most of toxin-based models do not show LB that matches the disease state,
and the site of injury is limited. Therefore, it is difficult to reproduce the chronic progression of the
disease along with the Braak stage. However, it is interesting to see how non-motor symptoms can be
reproduced by the functional abnormalities in these toxin-based models.
2.2.1. Olfactory Dysfunction in Toxin-Based Models
The intranasal administration of MPTP-reproduced transient olfactory disturbance in rats [50].
Olfactory disturbance was also observed in rats with rotenone administered to the SNc, and DA
produced by periglomerular neurons and D2 receptors in the olfactory bulb was thought to be important
for the olfactory discrimination ability according to DA agonist/antagonist administration experiments
in this model [51].
2.2.2. Constipation in Toxin-Based Models
MPTP exposure in mice has been shown to reduce the number of intestinal dopamine neurons
and cause GI dysfunction [52]. However, in this model, intestinal motility was actually increased,
and an electrophysiological study suggested the impaired neural-mediated relaxation of the colon.
A decreased number of TH cells in the myenteric plexus of the intestinal tract has also been reported
in an MPTP-treated primate model [53]. The chronic administration of low-dose rotenone to rats
caused α-syn aggregation mainly in the myenteric ganglia of the small intestine, and the number of
enteric neurons and GI motility were decreased 6 months after administration [54]. In a rat model
with subcutaneous rotenone injection, a longer gastric-emptying time and a transient decrease in stool
frequency were observed, but there was no α-syn pathology [55].
2.2.3. RBD in Toxin-Based Models
Increased muscle tone during REM sleep, which is suggestive of an RBD-like phenotype,
was reported in a 6-OHDA-treated rat model [56]. In this model, loss of DA neurons in the SNc was
considered to be responsible for RBD-like phenotype, as there were no obvious pathological changes
in the RBD-related regions, including the sublaterodorsal nucleus, which is equivalent to the locus
subcoeruleus in humans; in contrast, a reduction by over 95% in the number of TH-positive neurons
was noted in the SNc. In rhesus monkeys and marmosets treated with MPTP, the muscle tone was
increased during REM sleep [57,58]. All of the above-mentioned toxin-based models have already
shown motor symptoms accompanied by robust DA neuronal death, so these models may actually
reflect sleep disorders after the onset of motor symptoms in PD.
2.3. Prodromal Symptoms of Genetic Models
2.3.1. α-syn Genetic Models
In α-syn genetic models, it is important to consider that the phenotypes completely depend
on promoters. For example, α-syn can be overexpressed in a wide range of neurons by the prion
promoter, but it may cause toxicity in undesired regions such as spinal cords. When the TH promoter
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is used, α-syn can be overexpressed only in PD-vulnerable catecholaminergic neurons, but the effect
on other types of neurons such as cholinergic neurons cannot be evaluated. From this viewpoint,
transgenic models with endogenous promoters of α-syn using bacterial artificial chromosome (BAC)
and P1-derived artificial chromosome (PAC) harboring the gene expression regulatory region have
advantages, albeit the moderate expression level of transgene. In addition, because few models
exhibit DA neuronal loss and associated motor phenotype, the progression of prodromal to motor
phase is difficult to be assessed. Nonetheless, these models, even without DA cell loss, can be
useful for the development of symptomatic and disease-modifying therapies targeting α-syn-related
non-motor symptoms.
Prion Promoter
The transgenic mice overexpressing A53T α-syn under the prion promoter were first reported in
2002. They showed robust α-syn aggregation, especially in the spinal cord, leading to motor paralysis
and death. As for non-motor symptoms, it is reported that they showed a deficit of odor discrimination
and odor detection at 6 months [59]. In this report, the levels of phosphorylated α-syn and TH in
the olfactory bulb were increased, and cholinergic denervation of the mitral cell layer was observed
before the onset of motor symptoms. Another report showed that the GI motility was attenuated at 3
months, and α-syn aggregates were observed in the mesenteric and submucosal plexus of the colon [60].
These GI phenotypes were already observed when mice displayed only faint central nervous pathology
without motor symptoms, suggesting that this could be a viable model for premotor GI dysfunction.
Thy1 Promoter
Transgenic mice overexpressing wild-type α-syn under the Thy1 promotor showed hyposmia
and insoluble α-syn inclusion in the olfactory bulb at 3 to 5 months [61]. Anxiety appears at 4 months,
sleep disturbance occurs at 9–10 months, and colonic dysfunction are seen at 12 months. Although the
number of TH neurons in the SNc did not decrease even at 22 months, the locomotion became reduced
with the decrease of striatal DA content by 40% after 14 months, and it is considered to be attributed
to the DA terminal loss [62]. This model is especially useful to test the therapeutics to slow the
progression of the disease in a prodromal phase to the motor phase, and to test the effect of intervention
to prodromal symptoms on the development of motor symptoms.
Endogenous Promoter Using BAC or PAC
Transgenic human A53T α-syn mice with P1-derived artificial chromosome (PAC) on an
endogenous α-syn null background showed reduced intestinal motility and prolonged whole-gut
transit time at 3 months along with a decreased stool water content. Pathologically, α-syn was
accumulated in the intestinal submucosa and myenteric plexus [63]. They do not show olfactory
loss but show motor symptoms at 6 months. However, there are no significant TH neuronal loss
in SNc and decrease of the content of DA, norepinephrine, or serotonin in the striatum by HPLC.
In another report, wild-type human SNCA BAC transgenic mice showed no significant change in
the content of DA, norepinephrine, or serotonin by HPLC but exhibited increased dopamine and
serotonin transporter expression [22].Wild-type human SNCA BAC transgenic mice on an endogenous
α-syn null background exhibited a constipation-like phenotype that was only seen in male mice
before motor symptoms [64]. We recently reported A53T α-syn BAC transgenic mice showing an
RBD-like phenotype and hyposmia [65]. These mice exhibited REM sleep without atonia, which is a
key feature of RBD, at as early as 5 months of age, and olfactory dysfunction by 9 months. In these mice,
phosphorylated α-syn was found to be accumulated in the dorsomedial medulla and sublaterodorsal
nucleus, as well as the olfactory bulb, and the number of TH-positive neurons in the SNc was decreased
by 18% without motor symptoms at 18 months. This phenotype suggests that this is a prodromal
PD mouse model. Sleep abnormalities, most of which involve changes in the architecture of sleep,
have been reported in a number of animal models, so a comprehensive review of the rodent model
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would be useful [66]. However, there have been no α-syn-based genetic animal models reported that
exhibit RBD with the exception of the abovementioned A53T α-syn BAC transgenic mice.
In a rat model, wild-type α-syn BAC transgenic rats showed olfactory dysfunction at 3 months [67].
They showed a decrease in the content of DA in striatum by 30% at 6 months, followed by the motor
phenotype at 16 months. They also showed anxiety-like behaviors, but there are no significant changes
in the contents of noradrenaline and serotonin.
2.3.2. Other Genetic Models
Genetic mutations that lead to the formation of Lewy bodies are important for creating the
animal model of idiopathic PD. It has been reported that LRRK2 R1441C knock-in mice showed
reduced anxiety-like behaviors at about 8 to 10 months, and motor and olfactory dysfunction at
24 to 26 months [68]. In LRRK2 R1441G BAC transgenic mice, gastrointestinal dysfunctions began
at 6 months, followed by mild hypokinesia in the open field at 16 months, but other non-motor
phenotypes were not observed [69].
2.4. Prodromal Symptoms of α-syn Propagation Models
A lot of α-syn fibril injection models are reported, but models with injection into the olfactory
bulb and GI tract are especially important to trace the propagation of α-syn pathology and related
non-motor symptoms as well as to validate Braak’s hypothesis.
2.4.1. Olfactory Injection
According to a study in which α-syn fibrils were injected into the olfactory bulb of mice, olfactory
disturbance appeared after 1 month [70,71]. In these studies, phosphorylated α-syn first appeared in
the olfactory bulb, spread to the hippocampus and amygdala 3 months later, and was transmitted to
the SNc and locus coeruleus 12 months after the injection. However, they showed neither cognitive
decline, psychiatric symptoms, nor motor dysfunction.
2.4.2. GI Tract Injection
Several α-syn injection models into the GI tract have been reported. The initially reported
mice model injected with α-syn fibrils into the stomach showed the transient formation of α-syn
aggregates in the DMV without further upward propagation [31,32]. Similarly, injections of α-syn
fibrils into the colon of rats and non-human primates (cynomolgus monkeys) have only resulted in
faint brainstem lesions and transient GI symptoms [72]. However, mice injected with α-syn fibrils
into the stomach and duodenum exhibited propagation of α-syn pathology from the brainstem to the
midbrain, amygdala, hippocampus, and eventually to the olfactory bulb [33]. In accordance with this
pathological progression, the stool number per passage and water content were decreased at 1 month
post-inoculation (p.i.); motor symptoms, anxiety/depression, and memory impairment appeared at
7 months p.i.; finally, olfactory impairment appeared at 9 months p.i. in these mice. This important
propagation model partly reproduced the natural history of PD from the prodromal to symptomatic
stages. However, various factors, such as the method of fibril preparation, the site of injection, and the
amount of injected α-syn fibrils, seem to have effects on the degree of α-syn propagation so further
examinations will be necessary.
As a novel delivery method of α-syn fibrils, intravenous administration using rabies virus-derived
neuron-targeting peptide (RVG9R) has been reported [73]. In this model, non-motor symptoms,
such as diminished intestinal motility and olfactory disturbance, were recognized 6 months after the
administration of α-syn fibrils, and the accumulation of phosphorylated α-syn was observed in the
myenteric plexus of the duodenum. In the central nervous system, phosphorylated α-syn began
to accumulate in the DMV after 4 months, and the α-syn pathology spreads rostrally to the locus
coeruleus, the substantia nigra, and the cortex. However, the number of TH cells in the SNc was
decreased by only 15%-20%. Although the distribution of these lesions may depend on the cell-type
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preference of RVG9R as well as the expression of endogenous α-syn, it attracts attention as a novel
prodromal PD model.
3. Conclusions
A number of animal models have helped clarify the pathomechanisms underlying PD, but none
has faithfully reproduced the entire natural history of PD. An ideal model of prodromal PD is one
that reproduces several PD-specific premotor symptoms followed by the slowly progressive DA
neurodegeneration. From this viewpoint, mice with α-syn fibrils injected into the GI tract that show
hyposmia, GI symptoms, and DA cell loss with robust α-syn propagation seem to be a promising
model for prodromal PD, despite the artificial element of α-syn fibril inoculation. [33]. A53T SNCA
BAC transgenic mice also show both hyposmia and RBD symptoms with phosphorylated α-syn
accumulation and mild DA cell death in late stages [65]. This model partly reproduces the initiation
process of PD in that multiple non-motor symptoms, including hyposmia and RBD, are observed
before the onset of motor symptoms, which is difficult to fully explain by the α-syn propagation alone.
It is difficult to reproduce all the aspects of the preclinical, prodromal, and advanced stages of
PD in a single animal model, so models should be selected according to the experimental purpose.
If genetic factors are weighted,α-syn overexpression and the multiple initiation model are valued, and if
environmental factors are weighted, the α-syn propagation model is useful. In reality, the propagation
from the multiple initiation sites may be occurring in PD. α-Syn fibril injection to the GI tract and
olfactory bulb to humanα-syn transgenic mice will be useful to trace the progression ofα-syn pathology
and to test the therapeutics against the progression of human α-syn toxicity in vivo.
Animal models continue to play an important role in the field of PD research, and the prodromal
PD model will provide a substantial contribution to research efforts, especially the development of
DMT and early biomarkers for PD in the future.
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